Mar. 27, 2006 — Ablynx, a developer of nanobodies, a class of antibody-derived therapeutic proteins, announced that Edwin Moses has accepted its board’s offer to extend his role as chairman to include that of chief executive officer.
Moses has been non-executive chairman of Ablynx since November 2004. He takes over the CEO role from Mark Vaeck, who will continue to support the company in a consultative capacity.
Ablynx has signed collaborative drug discovery deals with Novartis, Centocor, Kirin Brewery and Procter & Gamble Pharmaceuticals.